3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Unknown
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Dermatologic
2
Conditions
Breast Neoplasms
22
Neoplasm Metastasis
15
Carcinoma, Non-Small-Cell Lung
7
Glioblastoma
6
Colorectal Neoplasms
5
Triple Negative Breast Neoplasms
4
Recurrence
4
Ovarian Neoplasms
4
Lymphoma, Mantle-Cell
4
Lymphoma, Follicular
4
Endometrial Neoplasms
4
Brain Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
3
Prostatic Neoplasms
3
Pancreatic Neoplasms
3
Neoplasms
3
Lymphoma, Large B-Cell, Diffuse
3
Lung Neoplasms
3
Hereditary Sensory and Autonomic Neuropathies
3
Head and Neck Neoplasms
3
Solid Tumors
2
Melanoma
2
Lymphoma
2
Leukemia, Myeloid, Acute
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Esophageal Neoplasms
2
Waldenstrom Macroglobulinemia
1
Unspecified Adult Solid Tumor, Protocol Specific
1
Treatment for Metastatic or Locally Advanced Cervical Cancer
1
Tongue Neoplasms
1
Interventions
pembrolizumab
287
Nivolumab
258
Ipilimumab
236
Cyclophosphamide
135
aldesleukin
134
Interleukin-2
104
Temozolomide
75
Dacarbazine
74
trametinib
70
Vemurafenib
69
fludarabine
68
dabrafenib
65
fludarabine phosphate
62
sargramostim
44
binimetinib
44
Radiosurgery
44
Biopsy
43
Paclitaxel
42
Bevacizumab
42
incomplete Freund's adjuvant
39
encorafenib
37
Radiotherapy
36
Cisplatin
36
CTLA-4 Antigen
36
atezolizumab
35
Carboplatin
35
Magnetic Resonance Spectroscopy
33
cobimetinib
32
Specimen Handling
30
Introns
30
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Melanoma
×
NVP-BKM120
×
Clear all
NCT02159066
2024-03-05
LOGIC-2
Pfizer
Phase 2
Completed
158 enrolled
40 charts
NCT02452294
2017-05-03
BUMPER
University Hospital Tuebingen
Phase 2
Unknown
22 enrolled